Attovia Therapeutics, Inc.
AI summary Insiders and major shareholders purchase shares in Attovia Therapeutics' upsized $289 million initial public offering.
- Research score
- 65
- AI adjustment
- -11
Research score, not a recommendation.
Market data
Live quote and chart from Yahoo Finance, loaded through this server. Insider purchases are marked on the chart.
–
partial data Price history is incomplete; missing inputs count as neutral in the score.
Why this score
Research score: a weighted blend of the five factors, times the routine and offering discounts, minus the selling penalty.
Why are they buying?
AI · ipo_offering · catalyst credible · documentedThe buying activity occurred in direct connection with the pricing and closing of Attovia Therapeutics' initial public offering on the Nasdaq, which raised $289 million in gross proceeds to fund clinical trials for its lead anti-itch biologic candidate.
Attovia Therapeutics completed its initial public offering of 17 million shares of common stock at a price of $17 per share, bolstered by strong investor demand and participation from major stakeholders like Sanofi, Redmile Group, and venBio.
Stock Price & Insider Purchase History
Daily close price with open-market insider purchases plotted over time
Loading price history…
| Date | Insider | Role | Shares | Price | Value | Flags | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-05 → 2026-08-06 | GOLDMAN SACHS & CO. LLC history of GOLDMAN SACHS & CO. LLC's purchases | Other | 585,000 | $17.58 avg | $10.3M | ||
| 2026-08-05 | GOLDMAN SACHS & CO. LLC | 85,000 | $21.00 | $1.8M | SEC filing for GOLDMAN SACHS & CO. LLC (opens in a new tab) | ||
| 2026-08-06 | GOLDMAN SACHS & CO. LLC | 500,000 | $17.00 | $8.5M | SEC filing for GOLDMAN SACHS & CO. LLC (opens in a new tab) | ||
| 2026-08-05 → 2026-08-06 | WALSH COLIN history of WALSH COLIN's purchases | Director | 585,000 | $17.58 avg | $10.3M | ||
| 2026-08-05 | WALSH COLIN | 85,000 | $21.00 | $1.8M | SEC filing for WALSH COLIN (opens in a new tab) | ||
| 2026-08-06 | WALSH COLIN | 500,000 | $17.00 | $8.5M | SEC filing for WALSH COLIN (opens in a new tab) | ||
| 2026-08-06 | Redmile Group, LLC history of Redmile Group, LLC's purchases | 10% owner | 600,000 | $17.00 avg | $10.2M | ||
| 2026-08-06 | Redmile Group, LLC | 400,000 | $17.00 | $6.8M | SEC filing for Redmile Group, LLC (opens in a new tab) | ||
| 2026-08-06 | Redmile Group, LLC | 200,000 | $17.00 | $3.4M | SEC filing for Redmile Group, LLC (opens in a new tab) | ||
| 2026-08-06 | FHMLS XI, L.P. history of FHMLS XI, L.P.'s purchases | 10% owner | 588,235 | $17.00 | $10.0M | SEC filing for FHMLS XI, L.P. (opens in a new tab) | |
| 2026-08-06 | venBio Global Strategic Fund IV, L.P. history of venBio Global Strategic Fund IV, L.P.'s purchases | 10% owner | 382,352 | $17.00 | $6.5M | SEC filing for venBio Global Strategic Fund IV, L.P. (opens in a new tab) | |
| 2026-08-06 | Sanofi history of Sanofi's purchases | 10% owner | 300,000 | $17.00 | $5.1M | SEC filing for Sanofi (opens in a new tab) | |
| Total | $52.4M | ||||||
What happened next
A run ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
After this run became a cluster: 21 days +14.7%63 days –126 days –